AK129 combination therapy for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new combination of drugs (including AK129) for people with advanced solid tumors, specifically lung cancer, head and neck cancer, or colorectal cancer. It is for those who have already tried a platinum chemo and a PD-1/PD-L1 drug but their cancer got worse.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- Your cancer is advanced (stage IIIB/C or IV) non-small cell lung cancer, or recurrent/metastatic head and neck cancer, or advanced colorectal cancer that is not MSI-high.
- You have not had any prior cancer treatment for your advanced disease, but you must have received a platinum-based chemo and a PD-1/PD-L1 drug and then your cancer worsened.
- You are in good physical condition (able to do daily activities without help) and expected to live more than 3 months.
- You do not have certain genetic changes (like EGFR, ALK, ROS1) in lung cancer or MSI-high in colorectal cancer.
- You do not have active brain metastases, autoimmune disease, serious infections, or lung inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a combination of two study medicines (AK119 plus AK112) in people with advanced solid tumors that have grown or didn’t respond to standard treatment. It may help shrink tumors or improve how long people can stay on treatment by blocking cancer-related pathways.
This trial tests a new combination of two immunotherapy drugs (AK112 and AK117) versus the standard immunotherapy pembrolizumab for people with advanced head and neck cancer that hasn't been treated before.
This trial tests a new drug, AK129, alone or with another drug called AK117, for people with classic Hodgkin lymphoma that has not responded to or stopped responding to PD-1/L1 inhibitor therapy. The goal is to see if these combinations can help control the cancer.
This Phase 1/2 trial tests a combination of two immune-targeting drugs (AK109 and AK104) in people with advanced solid tumors that can’t be treated with standard options, or where standard treatment didn’t work or wasn’t tolerated. It aims to find safe dosing and whether the treatment can shrink tumors or control the disease.
This trial tests a combination of two experimental immunotherapies (AK104 and AK109) with a standard chemo drug (paclitaxel) for people with advanced stomach or gastroesophageal junction cancer that has grown after initial treatment. The goal is to see if this new combination can help shrink tumors or slow the cancer better than chemo alone.
This study tests a new experimental drug called AK-1286 for people with advanced solid tumors that haven't responded to standard treatments. The goal is to see if the drug is safe and may help shrink tumors.
Hear when a new Non-small Cell Lung Cancer Stage IIIB/IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.